Literature DB >> 142712

[Computerized tomography of the facial skeleton (part II). Pathological changes (author's transl)].

F Lohkamp, C Claussen, H Spenneberg.   

Abstract

The value and main task of computerized tomography in the diagnosis of benign and malignant processes in the middle and upper facial skeleton lies in its accurate demonstration of the extent of the disease; this is important in relation to the planning of treatment, prognosis and to other complementary procedures. CT is a new and potent method for the TNM classification of tumours of the nose, paransal sinuses and nasal pharynx. The ability of the CT to demonstrate deeply situated structures in the face, without disturbing overlying shadows, makes precise staging of deep tumours possible, eg. stages T2-T4. The consequences in terms of pre-treatment TNM classification are discussed. In cases of fronto-basal fractures, the CT will show particularly trauma to the orbital contents, intracranial displacement of bone fragments and cerebral trauma with or without bleeding. Suspicion of orbital involvement by benign or malignant disease is a definite indication for a CT examination. As regards the middle and upper facial skeleton, computer tomography provides information of a morphological and quantitative nature and aids in the localisation of lesions. It should be properly integrated into the conventional clinical, endoscopic and tomographic methods employed in the diagnosis of lesions of the facial skeleton.

Entities:  

Mesh:

Year:  1977        PMID: 142712     DOI: 10.1055/s-0029-1230629

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  2 in total

Review 1.  [Competence and communication in the implementation of computer-assisted surgical planning].

Authors:  F Tavassol; N-C Gellrich
Journal:  Chirurg       Date:  2021-01-22       Impact factor: 0.955

2.  CT of the base of the skull.

Authors:  G B Bradac; J Schramm; T Grumme; R S Simon
Journal:  Neuroradiology       Date:  1978-11-24       Impact factor: 2.804

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.